366 related articles for article (PubMed ID: 24579331)
61. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts.
Junod B; Zahl PH; Kaplan RM; Olsen J; Greenland S
BMC Cancer; 2011 Sep; 11():401. PubMed ID: 21936933
[TBL] [Abstract][Full Text] [Related]
62. A reality check for overdiagnosis estimates associated with breast cancer screening.
Etzioni R; Xia J; Hubbard R; Weiss NS; Gulati R
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25362701
[TBL] [Abstract][Full Text] [Related]
63. [Benefits and limitations of mass screening. The natural history of breast cancer].
Tubiana M
Bull Acad Natl Med; 1998; 182(8):1593-610; discussion 1610-1. PubMed ID: 10188306
[TBL] [Abstract][Full Text] [Related]
64. Women's participation in breast cancer screening in France--an ethical approach.
Moutel G; Duchange N; Darquy S; de Montgolfier S; Papin-Lefebvre F; Jullian O; Viguier J; Sancho-Garnier H;
BMC Med Ethics; 2014 Aug; 15():64. PubMed ID: 25127662
[TBL] [Abstract][Full Text] [Related]
65. Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening.
Moss S
Breast Cancer Res; 2005; 7(5):230-4. PubMed ID: 16168145
[TBL] [Abstract][Full Text] [Related]
66. Overdiagnosis in breast cancer screening: The impact of study design and calculations.
Lynge E; Beau AB; Christiansen P; von Euler-Chelpin M; Kroman N; Njor S; Vejborg I
Eur J Cancer; 2017 Jul; 80():26-29. PubMed ID: 28535494
[TBL] [Abstract][Full Text] [Related]
67. Breast cancer screening controversy: too much or not enough?
Pivot X; Viguier J; Touboul C; Morère JF; Blay JY; Coscas Y; Lhomel C; Eisinger F
Eur J Cancer Prev; 2015 Jun; 24 Suppl():S73-6. PubMed ID: 26016791
[TBL] [Abstract][Full Text] [Related]
68. Mammography utilization in women aged 40-49 years: the French EDIFICE survey.
Pivot X; Eisinger F; Blay JY; Coscas Y; Calazel-Benque A; Viguier J; Roussel C; Morère JF
Eur J Cancer Prev; 2011 Jan; 20 Suppl 1():S16-9. PubMed ID: 21245674
[TBL] [Abstract][Full Text] [Related]
69. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis.
Zahl PH; Jørgensen KJ; Gøtzsche PC
Br J Cancer; 2013 Oct; 109(7):2014-9. PubMed ID: 23963144
[TBL] [Abstract][Full Text] [Related]
70. Summaries for patients: Overdiagnosis of invasive breast cancer with mammography screening.
Ann Intern Med; 2012 Apr; 156(7):I58. PubMed ID: 22473444
[No Abstract] [Full Text] [Related]
71. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Bevers TB; Helvie M; Bonaccio E; Calhoun KE; Daly MB; Farrar WB; Garber JE; Gray R; Greenberg CC; Greenup R; Hansen NM; Harris RE; Heerdt AS; Helsten T; Hodgkiss L; Hoyt TL; Huff JG; Jacobs L; Lehman CD; Monsees B; Niell BL; Parker CC; Pearlman M; Philpotts L; Shepardson LB; Smith ML; Stein M; Tumyan L; Williams C; Bergman MA; Kumar R
J Natl Compr Canc Netw; 2018 Nov; 16(11):1362-1389. PubMed ID: 30442736
[TBL] [Abstract][Full Text] [Related]
72. Register-based studies of cancer screening effects.
Von Euler-Chelpin M; Lynge E; Rebolj M
Scand J Public Health; 2011 Jul; 39(7 Suppl):158-64. PubMed ID: 21775376
[TBL] [Abstract][Full Text] [Related]
73. [A decentralized breast cancer screening program in the French department of Bas-Rhin].
Schaffer P; Gairard B; Guldenfels C; Haehnel P; Dale G; Bellocq JP; Renaud R
J Radiol; 2000 Aug; 81(8):845-57. PubMed ID: 10916002
[TBL] [Abstract][Full Text] [Related]
74. Missteps in Current Estimates of Cancer Overdiagnosis.
Lee CI; Etzioni R
Acad Radiol; 2017 Feb; 24(2):226-229. PubMed ID: 27894707
[TBL] [Abstract][Full Text] [Related]
75. EMAS position statement: individualized breast cancer screening versus population-based mammography screening programmes.
Depypere H; Desreux J; Pérez-López FR; Ceausu I; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; van der Schouw YT; Simoncini T; Tremollieres F; Rees M; EMAS
Maturitas; 2014 Dec; 79(4):481-6. PubMed ID: 25277123
[TBL] [Abstract][Full Text] [Related]
76. An open letter to panels that are deciding guidelines for breast cancer screening.
Kopans DB
Breast Cancer Res Treat; 2015 May; 151(1):19-25. PubMed ID: 25868866
[TBL] [Abstract][Full Text] [Related]
77. Breast cancer incidence: Decreasing trend in large tumours in women aged 50-74.
Molinié F; Delacour-Billon S; Tretarre B; Delafosse P; Seradour B; Colonna M
J Med Screen; 2017 Dec; 24(4):189-194. PubMed ID: 27810986
[TBL] [Abstract][Full Text] [Related]
78. [Breast cancer screening: The controversy continues… What's the interest for women?!].
Barranger E; Delpech Y
Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):325-326. PubMed ID: 28479072
[No Abstract] [Full Text] [Related]
79. Determination of thresholds of risk in women at average risk of breast cancer to personalize the organized screening program.
Bonnet E; Daures JP; Landais P
Sci Rep; 2021 Sep; 11(1):19104. PubMed ID: 34580360
[TBL] [Abstract][Full Text] [Related]
80. Analysis and classification of interval cancers in a French breast cancer screening programme (département of Isère).
Exbrayat C; Garnier A; Colonna M; Assouline D; Salicru B; Winckel P; Menegoz F; Bolla M
Eur J Cancer Prev; 1999 Jul; 8(3):255-60. PubMed ID: 10443955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
